ALAlejandro Martínez León

Alejandro Martínez León

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alejandro Martínez León has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospective discovery of LasB inhibitors by integrating generative design, free energy ranking, and experimental validation

    by Alejandro Martínez León, Angeliki Vgenopoulou, Gwenaëlle Jézéquel, Andreas M Kany, Anna Kh Hirsch, Jochen S Hub

    Identifying synthetically accessible, potent ligands from vast chemical space remains a major challenge in drug discovery, particularly because experimental synthesis and testing are costly and low throughput. Here, we present a fully open-source computational–experimental workflow that integrates fragment-based de novo molecular design with rigorous alchemical absolute binding free-energy calculations to enable physics-based prioritization before chemical synthesis. We apply this strategy by targeting the virulence-associated zinc metalloprotease LasB from Pseudomonas aeruginosa. From ~40,000 diverse compounds generated through multi-objective optimization, a small subset was prioritized and experimentally evaluated, leading to the discovery of three previously unreported nanomolar inhibitors (IC 50 22–53 nM) with excellent metabolic and plasma stability. This work demonstrates a general and scalable framework for coupling generative molecular design with quantitative binding affinity prediction, improving decision-making and reducing the cost, time, and risk associated with early-stage drug discovery.

  • Open Access

    Accelerating ligand discovery by combining Bayesian optimization with MMGBSA-based binding affinity calculations

    by Lucas Andersen, Max Rausch-Dupont, Alejandro Martínez León, Andrea Volkamer, Jochen S. Hub, Dietrich Klakow

    Combination of MD simulations with an active learning pipeline to bring an MD-level of accuracy to the drug discovery process of identifying the most potent binders. Evaluated on 60.000 computationally derived binding affinities of the MCL1 protein.

  • Open Access

    BindFlow: A Free, User-Friendly Pipeline for Absolute Binding Free Energy Calculations Using Free Energy Perturbation or MM(PB/GB)SA

    by Alejandro Martínez León, Lucas Andersen, Jochen S. Hub

    We present BindFlow, a Python-based software for automated absolute binding free energy (ABFE) calculations at the free energy perturbation (FEP) or at the molecular mechanics Poisson-Boltzmann/generalized Born surface area [MM(PB/GB)SA] level of theory. BindFlow is free, open-source, user-friendly, and easily customizable, runs on workstations or distributed computing platforms, and provides extensive documentation and tutorials. BindFlow uses GROMACS as a molecular dynamics engine and provides built-in support for the small-molecule force fields GAFF, OpenFF, and Espaloma, as well as support for user-provided custom force fields. We test BindFlow by computing affinities for 139 receptor-ligand pairs, involving eight different targets, including six soluble proteins, one membrane protein, and one nonprotein host-guest system. We find that the agreement of BindFlow predictions with experiments is overall similar to gold standards in the field. Interestingly, we find that MM(PB/GB)SA achieves correlations that, for some systems and force fields, approach those obtained with FEP while requiring only a fraction of the computational cost. This study establishes BindFlow as a validated and accessible tool for ABFE calculations.


  • Open Access

    BindFlow: a free, user-friendly pipeline for absolute binding free energy calculations using free energy perturbation or MM(PB/GB)SA

    by Alejandro Martínez León, Lucas Andersen, Jochen S. Hub

    We present BindFlow, a Python-based software for automated absolute binding free energy (ABFE) calculations at the free energy perturbation (FEP) or at the molecular mechanics Poisson-Boltzmann/generalized Born surface area [MM(PB/GB)SA] level of theory. BindFlow is free, open-source, user-friendly, easily customizable, runs on work-stations or distributed computing platforms, and provides extensive documentation and tutorials. BindFlow uses GROMACS as molecular dynamics engine and provides built-in support for the small-molecule force fields GAFF, OpenFF, and Espaloma. We test BindFlow by computing affinities for 139 ligand/target pairs, involving eight different targets including six soluble proteins, one membrane protein and one non-protein host– guest system. Quantified by Pearson, Kendall, and Spearman correlations coefficients, we find that the agreement of BindFlow predictions with experiments are overall similar to gold standards in the field. Interestingly, we find that MM(PB/GB)SA achieves correlations that, for some systems and force fields, approach those obtained with FEP, while requiring only a fraction of the computational cost. This study establishes BindFlow as a validated and accessible tool for ABFE calculations.

  • Open Access

    Accelerating ligand discovery by combining Bayesian optimization with MMGBSA-based binding affinity calculations

    by Lucas Andersen, Max Rausch-Dupont, Alejandro Martínez León, Andrea Volkamer, Jochen S. Hub, Dietrich Klakow

    Predicting protein–ligand binding affinity with high accuracy is critical in structure-based drug discovery. While docking methods offer computational efficiency, they often lack the precision required for reliable affinity ranking. In contrast, molecular dynamics (MD)-based approaches such as MMGBSA provide more accurate binding free energy estimates but are computationally intensive, limiting their scalability. To address this trade-off, we introduce an active learning framework that automates molecule selection for docking and MD simulations, replacing manual expert-driven decisions with a data-efficient, model-guided strategy. Our approach integrates fixed — partly pre-trained deep learning — molecular embeddings (MolFormer, ChemBERTa-2, and Morgan fingerprints) with adaptive regression models (e.g. Bayesian Ridge and Random Forest) to iteratively improve binding affinity predictions. We evaluate this approach retro-spectively on a new dataset of 59,356 chemically diverse compounds from ZINC-22 targeting the MCL1 protein using both AutoDock Vina and MMGBSA binding free energy scores. Our results show that incorporating MMGBSA scores into the active learning loop significantly enhances performance, recovering 79.9% of the top 1% binders in the whole dataset, compared to only 6.7% when using docking scores alone. Notably, MMGBSA exhibits a stronger correlation with experimental binding affinities than AutoDock Vina on our dataset and enables more accurate ranking of candidate compounds in a runtime efficient way. Furthermore, we demonstrate that a one-at-a-time acquisition active learning strategy consistently outperforms traditional batched acquisition, the latter achieving just 78.4% recovery with MolFormer and Bayesian Ridge. These findings underscore the potential of integrating deep learning-based molecular representations with MD-level accuracy in an active learning framework, offering a scalable and efficient path to accelerate virtual screening and improve hit identification in drug discovery.


  • Top Cited Papers
    Open Access

    Structural insights into tecovirimat antiviral activity and poxvirus resistance

    by Riccardo Vernuccio, Alejandro Martínez León, Chetan S. Poojari, Julian Buchrieser, Christopher N. Selverian, Yakin Jaleta, Annalisa Meola, Florence Guivel-Benhassine, Françoise Porrot, Ahmed Haouz, et al.

    Mpox is a zoonotic disease endemic to Central and West Africa. Since 2022, two human-adapted monkeypox virus (MPXV) strains have caused large outbreaks outside these regions. Tecovirimat is the most widely used drug to treat mpox. It blocks viral egress by targeting the viral phospholipase F13; however, the structural details are unknown, and mutations in the F13 gene can result in resistance against tecovirimat, raising public health concerns. Here we report the structure of an F13 homodimer using X-ray crystallography, both alone (2.1 Å) and in complex with tecovirimat (2.6 Å). Combined with molecular dynamics simulations and dimerization assays, we show that tecovirimat acts as a molecular glue that promotes dimerization of the phospholipase. Tecovirimat resistance mutations identified in clinical MPXV isolates map to the F13 dimer interface and prevent drug-induced dimerization in solution and in cells. These findings explain how tecovirimat works, allow for better monitoring of resistant MPXV strains and pave the way for developing more potent and resilient therapeutics.


  • Open Access

    Moldrug algorithm for an automated ligandbinding site exploration by 3D aware molecular enumerations

    by Alejandro Martínez León, Benjamin Ries, Jochen Hub, Aniket Magarkar

    We present Moldrug, a computational tool for accelerating the hit-to-lead phase in structure-based drug design. Moldrug explores the chemical space using structural modifications suggested by the CReM library and by optimizing an adaptable fitness function with a genetic algorithm. Moldrug is complemented by Moldrug-Dashboard, a cross-platform and user-friendly graphical interface tailored for the analysis of Moldrug simulations. To illustrate Moldrug, we designed new potential inhibitors targeting the main protease (MPro) of SARS-CoV-2 by optimizing a consensus fitness function that balances binding affinity, drug-likeness, and synthetic accessibility. The designed molecules exhibited high chemical diversity. A subset of the designed molecules were ranked using MM/GBSA and alchemical binding free energy calculations, revealing predicted affinities as low as −10 kcal mol−1. Moldrug is distributed as a Python package under the Apache 2.0 license. It offers pre-configured multi-parameter fitness functions for molecular design, while being highly adaptable for integrating functionalities from external software. Documentation and tutorials are available at https://moldrug.rtfd.io.

  • Open Access

    Mechanisms of Tecovirimat Antiviral Activity and Poxvirus Resistance

    by Riccardo Vernuccio, Alejandro Martínez León, Chetan Poojari, Julian Buchrieser, Christopher Selverian, Yakin Jaleta, Annalisa Meola, Florence Guivel-Benhassine, Françoise Porrot, Ahmed Haouz, et al.

    Mpox is a zoonotic disease endemic in central and west Africa. However, since 2022, human-adapted mpox virus (MPXV) strains are causing large outbreaks spreading outside these regions, leading the World Health Organization to declare public health emergency twice. Tecovirimat, the most widely used drug to treat these infections, blocks viral egress through a poorly understood mechanism. Tecovirimat-resistant strains, all with mutations in the viral phospholipase F13, pose public health concerns. Herein, we report the structure of an F13 homodimer, both alone and in complex with tecovirimat. We demonstrate that tecovirimat acts as a molecular glue, inducing the dimerization of the phospholipase. F13 escape mutations in MPXV clinical isolates are at the dimer interface and prevent drug-induced dimerization in solution and cells. These findings, which decipher tecovirimat's mode of action, will allow better monitoring of poxvirus outbreaks and pave the way for developing more potent and resilient therapeutics.